IDI WKN A2DTEB | ISIN CH0363463438 | Option Watchlist Musterdepot Alert - - CHF - (-) EUREX SIX Swiss Exchange Nasdaq Other OTC Baader Bank (Baadex) Lang & Schwarz EUREX gettex Hamburg München Verkaufen Kaufen Übersicht Chart-Pro Nachrichten Kurse & Handelsplätze 20.12.24 ROUNDUP/Aktien Europa Schluss: EuroStoxx reduziert Verluste - Positive US-Börsen 02.09.24 ROUNDUP 2: Massenproteste in Israel nach Bergung toter Gaza-Geiseln 02.09.24 ROUNDUP: Massenproteste in Israel nach Bergung toter Gaza-Geiseln 03.06.24 GNW-Adhoc: New data with daridorexant to be presented at SLEEP 2024 31.05.24 GNW-Adhoc: Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 23.05.24 GNW-Adhoc: Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders 21.05.24 GNW-Adhoc: Idorsia announces changes to Idorsia Executive Committee and Board of Directors 21.05.24 GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor 21.05.24 GNW-Adhoc: Idorsia announces financial results for the full year of 2023 - Adapting the company to create sustainable value 14.05.24 GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call 06.05.24 GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds 01.05.24 GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond 26.04.24 GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension 23.04.24 GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting 17.04.24 GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting